IMIO

IMIO is a provider of agricultural biologicals that improve crop performance, nutrient efficiency, and soil function. From its funding announcement.

$12M UndisclosedRaised yesterdayChicago, USABiotech & PharmaUSA
Visit website →

In their own words

What IMIO says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "provider of agricultural biologicals that improve crop performance, nutrient efficiency, and soil function". Source

Manufacturing and scale

Public signal Read from the company's own description of what the funding supports.

Why now

Where IMIO is today

IMIO announced a funding round of $12M on 20 October 2026, led by Sofinnova Partners.

Latest round
Undisclosed
Amount
$12M
Announced
20 October 2026
Headquarters
Chicago, USA
Sector
Biotech & Pharma
Growth stage
Growth
Investors
Also participating
Chipotle's Cultivate Next venture fund, Starshot Capital, Grow Together Fund, Earth Foundry, Serra Ventures
Relevant leadership
Founder and CEO Charles Smith

Momentum AfterRaise intelligence

AfterRaise Score

62
Building momentum
1 funding signal in the last 90 days
Funding recency
40/40
announced within the last 30 days
Round scale
12/25
round size relative to the market
Funding stage
10/20
Undisclosed
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 20 October 2026
    $12M raised
    Led by Sofinnova Partners.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • Manufacturing capacity expansion
  • Senior operations hiring
  • Supply-chain build-out
  • Operational scale

Opportunities this could create

  • CMC and manufacturing
  • Quality systems
  • Licensing and BD partnerships
  • Manufacturing leadership
  • Supply-chain partners

Based on the Biotech & Pharma sector, a Growth round and the priorities the company itself set out. Not a statement of fact.

Medium momentum2 connected signals
  • 20 October 2026$12M round announced
  • 20 October 2026Stated priority: manufacturing and scale

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What IMIO is open to

Not yet specified

IMIO has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with IMIO

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at IMIO?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

What we do not have yet: the roles and projects you have open. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Biotech & Pharma companies

See the sector